Global Ziprasidone Market Size, Share and Trends Analysis Report, By Type (Oral Capsule and Injections), By Application (Hospitals and Drug Store), Forecast (2022-2028)

The global ziprasidone market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Ziprasidone is prescribed by doctors as a mood stabilizer for the maintenance treatment of bipolar disorders. Ziprasidone drug is also used to treat the symptoms of schizophrenia disorder. The market is growing due to the increased prevalence of bipolar disorder disease as well as rising initiatives by government institutions to increase awareness among the population.  According to the Institute for Health Metrics and Evaluation, the prevalence of bipolar disorder varies from 0.3 to 1.2 by country. In 2017, almost 46 million people in the world had bipolar disorder with men holding 48% share and females holding 52% share globally. The typical age for this disease to grow is mostly in the early 20s. According to National Alliance on Mental Illness, an estimation of 1 in every 5 adults in the US experiences mental illness every year. According to World Health Organization, bipolar disorder is considered the sixth leading cause of disability in the world. According to the Nation Institute of Medical Health, bipolar disorder almost reduces 9.2 years of expected life span and almost one in every five bipolar disorder patients commits suicide. Hence, the rise in the cases of bipolar disorder and the increasing need to manage the disease effectively is boosting the growth of the ziprasidone market growth in the forecast period.

For instance, in March 2020, Dr. Reddy’s Laboratories Ltd. announced their approval from the US Food and Drug Administration for launching generic Ziprasidone injection used for the treatment of acute agitation in schizophrenic patients that will be available in 20 mg/ml single-dose vials in US market.

Some major players in the market include Dr. Reddy’s Laboratories Ltd., Pfizer Inc., Lupin, Mylan N.V., Aurobindo Pharma, and WOCKHARDT among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new drug launches, to stay competitive in the market. In June 2021, USFDA approved a new drug option to treat patients with schizophrenia and bipolar disorder I which is a combination of olanzapine and samidorphan and can be taken once daily. Several other drugs are in the pipeline which will be a combination of old drugs with new drug types that are intended for the treatment of bipolar disorder more effectively.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Reddy’s Laboratories Ltd., Pfizer Inc., Lupin, Mylan N.V., Aurobindo Pharma, and WOCKHARDT among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ziprasidone Market Report by Segment

By Type

• Oral capsule
• Injection

 

By Indication

 

• Hospital
• Drug Store

 

Global Ziprasidone Market Report by Region

 

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa